Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 193

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 5
Chunk 193
---
                                                             ​   ​              ​   ​       ​               ​   ​   ​       
Profit/loss (-) before tax                                    ​   ​        (3,085)   ​       ​           5,625   ​   (155%)  
​                                                             ​   ​              ​   ​       ​               ​   ​   ​       
Income taxes                                                  ​   ​          1,803   ​       ​         (9,613)   ​   (119%)  
​                                                             ​   ​              ​   ​       ​               ​   ​   ​       
Net loss from continuing operations                           ​   ​        (1,282)   ​       ​         (3,988)   ​   (68%)   
​                                                             ​   ​              ​   ​       ​               ​   ​   ​       
Net profit from discontinued operations, net of tax           ​   ​         75,364   ​       ​         215,685   ​   (65%)   
​                                                             ​   ​              ​   ​       ​               ​   ​   ​       
Net profit                                                    ​   €         74,082   ​       €         211,697   ​   ​       
​                                                             ​   ​              ​   ​       ​               ​   ​   ​       
Net profit attributable to:                                   ​   ​              ​   ​       ​               ​   ​   ​       
Owners of the parent                                          ​   ​         74,082   ​       ​         211,697   ​   ​       
Basic and diluted earnings per share                          ​   €           1.12   ​       €            3.21   ​   ​       
Basic and diluted loss per share from continuing operations   ​   €         (0.02)   ​       €          (0.06)   ​   ​       
​
​

​
140

Results from Discontinued Operations
On October 30, 2023 we announced that we had signed a letter of intent contemplating a transfer of the Jyseleca® business to Alfasigma, including the European and UK Marketing Authorizations, the commercial, medical and development activities for Jyseleca® and approximately 400 positions in 14 European countries.
On December 30, 2023, we signed a final share and asset purchase agreement with Alfasigma. 
On December 31, 2023, the transaction was still subject to certain closing conditions such as the finalization of the consultation process with the workers councils and FDI